ClinicalTrials.gg
RecruitingNCT06868199Updated Sep 12, 2025

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

A Phase 1/2 interventional study of LM-168 and Toripalimab in Advanced Solid Tumours, sponsored by LaNova Medicines Limited. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours.

For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.

02

Conditions studied

  • Advanced Solid Tumours
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Aged ≥18 years old (including boundary values) , male or female.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. In dose escalation stage, subjects must have histological or cytological confirmation of recurrent or advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
  6. In dose expansion stage, subjects must have histological or cytological confirmation of selected advanced solid tumors.
  7. Pre-treatment archived tumour tissue or on-treatment tumour could be provided for biomarker analysis optionally.
  8. At least one .
  9. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
  10. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-168.
  2. Having received prior or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with LM-168 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
  3. Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-168.
  4. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of v5.0.
  5. Subjects with uncontrolled tumour-related pain.
  6. Subjects with known central nervous system (CNS) or meningeal .
  7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
  8. Subjects with esophageal or gastric varices requiring immediate intervention, or those with a history of variceal bleeding.
  9. Hepatic encephalopathy, hepatorenal syndrome, class B or more severe liver cirrhosis.
  10. Tumor invasion of surrounding vital organs or a risk of developing esophagotracheal fistula or esophagopleural fistula.
  11. Patients with a history of active or previously confirmed inflammatory bowel disease.
  12. Subjects who experienced grade 3 or higher to the treatment that contains monoclonal antibody.
  13. Subjects who previously experienced grade ≥ 3 immune-related adverse events during immunotherapy, as well as subjects who discontinued prior immunotherapy due to severe or life-threatening immune-related adverse events.
  14. Subjects who take systemic (> 10 mg daily prednisone equivalents) or other systemic medications within 2 weeks prior to the first dosing of LM-168.
  15. Subjects with the known history of disease.
  16. Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia , drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis or evidence of active pneumonitis on screening chest CT scan.
  17. Use of any within 28 days prior to 1st dosing of LM-168.
  18. Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
  19. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of LM-168.
  20. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-168 (excluding tumour , puncture, etc.).
  21. Subjects who have severe cardiovascular disease.
  22. Subjects who have uncontrolled or severe illness.
  23. Subjects who have a history of immunodeficiency disease.
  24. infection, active infection including tuberculosis, and infection.
  25. Subjects with a history of other within 5 years prior to the first administration of the study drug.
  26. female who have positive results in pregnancy test or are lactating.
  27. Subjects who have psychiatric illness or disorders that may preclude study compliance.
  28. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    LM-168 Dose Escalation

    Drug: LM-168

  • Experimental
    LM-168 Dose Expansion

    Drug: LM-168

  • Experimental
    LM-168 combination dose escalation

    Drug: LM-168 · Drug: Toripalimab

  • Experimental
    LM-168 combination dose expansion

    Drug: LM-168 · Drug: Toripalimab

Interventions

  • DrugLM-168

    Q3W,Intravenous Drip

  • Q3W,Intravenous

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Phase I

    Time frame: 78 weeks

  2. Incidence of dose-limitingtoxicity (DLT)

    Phase I

    Time frame: 78 weeks

  3. Incidence of serious adverse event (SAE)

    Phase I

    Time frame: 78 weeks

  4. Temperature (Celsius)

    Phase I

    Time frame: 78 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase I

    Time frame: 78 weeks

  6. Blood Pressure in mmHg

    Phase I

    Time frame: 78 weeks

  7. Weight in Kg

    Phase I

    Time frame: 78 weeks

  8. Height in centimeter

    Phase I

    Time frame: 78 weeks

  9. Blood Routine examination

    Phase I

    Time frame: 78 weeks

  10. Urine Routine test

    Phase I

    Time frame: 78 weeks

  11. Blood biochemistry test

    Phase I

    Time frame: 78 weeks

  12. Coangulation function test

    Phase I

    Time frame: 78 weeks

  13. Thyroid function test

    Phase I

    Time frame: 78 weeks

  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase I

    Time frame: 78 weeks

  15. 12-lead electrocardiogram (ECG) in HR

    Phase I

    Time frame: 78 weeks

  16. 12-lead electrocardiogram (ECG) in RR

    Phase I

    Time frame: 78 weeks

  17. 12-lead electrocardiogram (ECG) in PR

    Phase I

    Time frame: 78 weeks

  18. 12-lead electrocardiogram (ECG) in QRS

    Phase I

    Time frame: 78 weeks

  19. 12-lead electrocardiogram (ECG) in QT

    Phase I

    Time frame: 78 weeks

  20. 12-lead electrocardiogram (ECG) in QTcF

    Phase I

    Time frame: 78 weeks

  21. ECOG(Eastern Cooperative Oncology Group) score

    Phase I

    Time frame: 78 weeks

  22. Objective Response Rate (ORR)

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Phase I

    Time frame: 78 weeks

  2. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Time frame: 130 weeks

  3. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Time frame: 130 weeks

  4. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase I/II

    Time frame: 130 weeks

  5. PK Parameter: Steady State Maximum Concentration(Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Time frame: 130 weeks

  6. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase I/II

    Time frame: 130 weeks

  7. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Time frame: 130 weeks

  8. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Time frame: 130 weeks

  9. PK Parameter: Elimination Half-life (t1/2)

    Phase I/II

    Time frame: 130 weeks

  10. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Time frame: 130 weeks

  11. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Time frame: 130 weeks

  12. Immunogenicity testing

    Phase I/II

    Time frame: 130 weeks

  13. Duration of Response (DOR) in Month

    Phase I/II

    Time frame: 130 weeks

  14. Disease control rate (DCR) in percentage

    Phase I/II

    Time frame: 130 weeks

  15. progression-free survival (PFS) in Month

    Phase I/II

    Time frame: 130 weeks

  16. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Time frame: 130 weeks

  17. Temperature (Celsius)

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  18. Pulse in BPM(Beat per Minute)

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  19. Blood Pressure in mmHg

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  20. Weight in Kg

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  21. Height in centimeter

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  22. Blood Routine examination

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  23. Urine Routine test

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  24. Blood biochemistry test

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  25. Coangulation function test

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  26. Thyroid function test

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  27. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

  28. ECOG(Eastern Cooperative Oncology Group) score

    Phase II

    Time frame: From 78th week to 130th week (52 weeks in total)

07

Study locations

5 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Mar 10, 2025
StartActual
May 6, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868199
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
May 6, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Sep 12, 2025

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211
Paul Kong
Contact
paulkong@lanovamed.com
+8613564682439
Sherry Qin
study director · LaNova Medicines Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion